ArticleEuropean radiology2022
[
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- COVID-19 vaccine associated axillary lymphadenopathy - A systematic review.Cancer treatment and research communications · 2022Pooled it
- COVID-19 Vaccination and Pulmonary Nodules: A Narrative Review of Causality, Detection Bias and Thoracic Imaging Pitfalls.Vaccines · 2026Review
- The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury.Advances in virology · 2025Review
- Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies.International journal of environmental research and public health · 2024Observational
- Distinguishing Axillary Lymphadenopathy after COVID-19 Vaccination from Malignant Lymphadenopathy.Journal of clinical medicine · 2024Article
- Examination of iatrogenic FDG accumulation after COVID-19 vaccination.Annals of nuclear medicine · 2024Article
- Morphological and Metabolic Criteria of COVID-19 Vaccine Associated Axillary Nodes on 18-Fluorodeouxyglucose PET/CT Imaging in Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy onEuropean journal of medical research · 2023Article
- Characterization of hypermetabolic lymph nodes after SARS-CoV-2 vaccination using PET-CT derived node-RADS, in patients with melanoma.Scientific reports · 2023Article
- Prolonged generalized immune response onRadiology case reports · 2023Article
- [Diagnostics (Basel, Switzerland) · 2023Article
- Axillary Lymph Node Uptake onMolecular imaging and radionuclide therapy · 2023Article
- Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?Gynecologic oncology reports · 2023Article
- Prone versus Supine FDG PET/CT in the Staging of Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- COVID-19 vaccine related hypermetabolic lymph nodes on PET/CT: Implications of inflammatory findings in cancer imaging.Oncology research · 2023Article
- The Clinical Utility of Molecular Imaging in COVID-19: An Update.Seminars in nuclear medicine · 2023Review
- [Clinical and translational imaging · 2023Article
- Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing anDiagnostics (Basel, Switzerland) · 2022Article
- COVID-19 vaccine-induced lymphadenopathies: incidence, course and imaging features from an ultrasound prospective study.Journal of ultrasound · 2022Article
- Evaluation of metabolic changes in FDG PET/CT imaging after mRNA-based COVID-19 vaccination.Turkish journal of medical sciences · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesTo assess the frequency, intensity, and clinical impact of [
methodsOne hundred forty patients referred for FDG PET/CT during February and March 2021 after first or second vaccination with Pfizer-BioNTech or Moderna were retrospectively included. FDG-avidity of ipsilateral axillary lymph nodes was measured and compared. Assuming no knowledge of prior vaccination, metastatic risk was analyzed by two readers and the clinical impact was evaluated.
resultsFDG PET/CT showed FDG-avid lymph nodes ipsilateral to the vaccine injection in 75/140 (54%) patients with a mean SUV
conclusionsFDG-avid axillary lymph nodes are common after COVID-19 vaccination. The avidity of lymph nodes is more frequent in Moderna compared to that in Pfizer-BioNTech vaccines. To avoid relatively frequent clinical dilemmas, we recommend carefully taking the history for prior vaccination in patients undergoing FDG PET/CT and administering the vaccine contralateral to primary cancer. KEY POINTS: • PET/CT showed FDG-avid axillary lymph nodes ipsilateral to the vaccine injection site in 54% of 140 oncological patients after COVID-19 vaccination. • FDG-avid lymphadenopathy was observed significantly more frequently in Moderna compared to patients receiving Pfizer-BioNTech-vaccines. • Patients should be screened for prior COVID-19 vaccination before undergoing PET/CT to enable individually tailored recommendations for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.